Physician profile
Mark Wasserman
NPI 1225130933
$941.64
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $161 · 2021: $407 · 2024: $34.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $34.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $34.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $282.64 | 2019-2021 | |
| Mylan Pharmaceuticals INC. | $60.15 | 2021 | |
| Covidien Lp | $59.86 | 2019 | |
| Agile Therapeutics, INC. | $57.95 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.13 | 2019-2020 | |
| Glaxosmithkline, LLC. | $51.20 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.46 | 2019 | |
| Mayne Pharma Commercial LLC | $48.31 | 2021 | |
| Merck Sharp & Dohme LLC | $47.07 | 2020-2021 | |
| Exeltis, USA INC. | $31.58 | 2019-2020 | |
| Daiichi Sankyo INC. | $24.98 | 2019 | |
| Lilly USA, LLC | $18.05 | 2024 | Mounjaro |
| Sumitomo Pharma America, INC. | $16.18 | 2024 | Gemtesa |
| Avion Pharmaceuticals | $15.94 | 2020 | |
| Ironshore Pharmaceuticals INC. | $15.67 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $15.31 | 2019 | |
| Duchesnay USA Incorporated | $15.27 | 2019 | |
| Myovant Sciences INC. | $14.62 | 2021 | |
| Allergan, INC. | $13.87 | 2020 | |
| Therapeuticsmd, INC. | $13.77 | 2021 | |
| Sage Therapeutics, LLC | $13.47 | 2021 | |
| Pfizer INC. | $12.28 | 2021 | |
| Minerva Surgical, INC | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Wasserman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.